Status | Study |
Recruiting |
Study Name: Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older Condition: Acute Lymphoblastic Leukemia (ALL) Newly Diagnosed Philadelphia Chromo Date: 2016-01-05 Interventions: Drug: Erwinia Chrysanthemi asparaginase |
Recruiting |
Study Name: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults Condition: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia Date: 2015-11-25 |
Recruiting |
Study Name: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults Condition: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Date: 2015-11-19 Interventions: Drug: Nilotinib 400 mg/12h per |
Recruiting |
Study Name: A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Condition: Chronic Myelogenous Leukemia Philadelphia Chromosome-positive A Date: 2014-02-28 Interventions: Drug: ABL001 ABL001 will be ad |
Active, not recruiting |
Study Name: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Condition: Childhood Acute Lymphoblastic Leukemia Philadelphia Chromosome, Date: 2013-11-16 Interventions: Drug: Idarubicin(IDA) 6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or |
Terminated |
Study Name: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia Ste Date: 2013-06-14 Interventions: Drug: TKI Imatinib will be given for patients without BCR/ABL mutations with a dose of 400mg/d or 600mg/ |
Withdrawn |
Study Name: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia Condition: B-cell Adult Acute Lymphoblastic Leukemia Blastic Phase Chronic Myelogenous Leukemia Date: 2012-08-17 Interventions: Drug: nilotinib Given PO |
Active, not recruiting |
Study Name: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Condition: Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, Date: 2012-04-20 Interventions: Drug: Radotinib 50mg, 100mg or 200mg Capsule BID Oth |
No longer available |
Study Name: Compassionate Use Ponatinib Condition: Philadelphia Chromosome Positive (Ph+) Leukemias Chronic Myeloi Date: 2012-03-06 Interventions: Drug: Ponatinib Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomac |
Completed |
Study Name: A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Condition: Myelogenous Leukemia, Chronic Date: 2012-01-01 Interventions: Drug: flumatinib Flumatinib wa |